HYDROMORPHONE HYDROCHLORIDE INJECTION, USP SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

HYDROMORPHONE HYDROCHLORIDE

Tilgjengelig fra:

FRESENIUS KABI CANADA LTD

ATC-kode:

N02AA03

INN (International Name):

HYDROMORPHONE

Dosering :

10MG

Legemiddelform:

SOLUTION

Sammensetning:

HYDROMORPHONE HYDROCHLORIDE 10MG

Administreringsrute:

INTRAMUSCULAR

Enheter i pakken:

15G/50G

Resept typen:

Narcotic (CDSA I)

Terapeutisk område:

OPIATE AGONISTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0108698001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2019-08-21

Preparatomtale

HYDROmorphone Hydrochloride Injection, USP - 2 mg/mL
Page 1 of 34
PRESCRIBING INFORMATION
INCLUDING PATIENT MEDICATION INFORMATION
N
HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
(Hydromorphone Hydrochloride Injection, USP)
2 mg/mL Sterile Solution for Injection
Intramuscular, Intravenous, Subcutaneous
Opioid Analgesic
NOT A PRODUCT MONOGRAPH
Fresenius Kabi Canada Ltd.
Date of revision:
165 Galaxy Blvd. Suite 100
August 20, 2019
Toronto, Ontario
M9W 0C8
Submission Control No.: 212894
HYDROmorphone Hydrochloride Injection, USP - 2 mg/mL
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................. 3
SUMMARY PRODUCT INFORMATION
........................................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................................
3
CONTRAINDICATIONS
...................................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................
12
DRUG INTERACTIONS
..................................................................................................................
15
DOSAGE AND ADMINISTRATION
..............................................................................................
16
OVERDOSAGE
................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
............................................................................
20
STORAGE AND STABILITY
.........................................................................................................
22
SPECIAL HANDLING INSTRUCTIONS
.....................................................